Stability of preferences for end-of-life treatment after 3 years of follow-up: The Johns Hopkins precursors study

Marsha N. Wittink, Knashawn H. Morales, Lucy A. Meoni, Daniel E. Ford, Nae Yuh Wang, Michael J. Klag, Joseph J. Gallo

Research output: Contribution to journalArticlepeer-review


Background: Preferences for life-sustaining treatment elicited in one state of health may not reflect preferences in another state of health. Methods: We estimated the stability of preferences for end-of-life treatment across 3 years and whether declines in physical functioning and mental health were associated with changes in preferences for end-of-life treatment. In this longitudinal cohort study of medical students in the graduating classes of 1948 to 1964 at Johns Hopkins University, 818 physicians completed the life-sustaining treatment questionnaire in 1999 and 2002 (mean age at baseline, 69 years). Results: Although the prevalence of the 3 clusters of life-sustaining treatment preferences remained stable across the 3-year follow-up, certain physicians changed their preferences with time. The probability that physicians were in the same cluster at follow-up as at baseline was 0.41 for "most aggressive," 0.50 for "intermediate care," and 0.80 for "least aggressive." Physicians without advance directives were more likely to transition to the most aggressive cluster than to the least aggressive cluster during the 3-year follow-up (odds ratio, 1.96; 95% confidence interval, 1.11-3.45). Age at baseline and decline in physical and mental health were not associated with transitions between 1999 and 2002. Conclusion: Periodic reassessment of preferences is most critical for patients who desire aggressive end-of-life care or who do not have advance directives.

Original languageEnglish (US)
Pages (from-to)2125-2130
Number of pages6
JournalArchives of internal medicine
Issue number19
StatePublished - Oct 27 2008

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Stability of preferences for end-of-life treatment after 3 years of follow-up: The Johns Hopkins precursors study'. Together they form a unique fingerprint.

Cite this